Matthew McQueen
Concepts (508)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 22 | 2022 | 1398 | 1.950 |
Why?
| | Polymorphism, Single Nucleotide | 40 | 2020 | 2143 | 1.750 |
Why?
| | Genetic Predisposition to Disease | 26 | 2022 | 2368 | 1.400 |
Why?
| | Genetic Linkage | 10 | 2011 | 292 | 1.300 |
Why?
| | Troponin I | 9 | 2020 | 81 | 1.130 |
Why?
| | Troponin T | 9 | 2020 | 65 | 1.060 |
Why?
| | Waist-Height Ratio | 3 | 2016 | 7 | 1.020 |
Why?
| | Risk-Taking | 4 | 2015 | 345 | 0.830 |
Why?
| | Body Mass Index | 12 | 2015 | 2382 | 0.810 |
Why?
| | Genetic Testing | 9 | 2016 | 457 | 0.720 |
Why?
| | Acute Coronary Syndrome | 6 | 2020 | 281 | 0.700 |
Why?
| | Sexual Behavior | 3 | 2013 | 487 | 0.680 |
Why?
| | Bipolar Disorder | 5 | 2011 | 268 | 0.650 |
Why?
| | Alcohol Drinking | 7 | 2022 | 819 | 0.640 |
Why?
| | Siblings | 7 | 2014 | 216 | 0.630 |
Why?
| | Quantitative Trait, Heritable | 5 | 2016 | 123 | 0.580 |
Why?
| | Genome, Human | 9 | 2014 | 418 | 0.570 |
Why?
| | Myocardial Infarction | 10 | 2020 | 1055 | 0.570 |
Why?
| | Epidemiology | 1 | 2018 | 33 | 0.570 |
Why?
| | Genotype | 18 | 2019 | 1873 | 0.570 |
Why?
| | Cardiovascular Diseases | 13 | 2024 | 2042 | 0.560 |
Why?
| | Metabolic Syndrome | 2 | 2016 | 348 | 0.540 |
Why?
| | Substance-Related Disorders | 8 | 2020 | 1080 | 0.540 |
Why?
| | Quantitative Trait Loci | 4 | 2015 | 376 | 0.530 |
Why?
| | Brain Concussion | 2 | 2021 | 579 | 0.500 |
Why?
| | Databases, Genetic | 5 | 2012 | 241 | 0.500 |
Why?
| | Alzheimer Disease | 8 | 2011 | 566 | 0.490 |
Why?
| | Teaching | 1 | 2018 | 229 | 0.480 |
Why?
| | Longitudinal Studies | 15 | 2024 | 2837 | 0.480 |
Why?
| | Antisocial Personality Disorder | 2 | 2015 | 152 | 0.480 |
Why?
| | Education, Medical, Undergraduate | 1 | 2018 | 190 | 0.470 |
Why?
| | Waist Circumference | 1 | 2015 | 139 | 0.470 |
Why?
| | Alcoholism | 8 | 2020 | 819 | 0.460 |
Why?
| | Athletic Injuries | 2 | 2021 | 535 | 0.460 |
Why?
| | Receptors, Nicotinic | 7 | 2013 | 345 | 0.460 |
Why?
| | Humans | 122 | 2024 | 138201 | 0.460 |
Why?
| | Genetic Variation | 8 | 2022 | 1002 | 0.440 |
Why?
| | Obesity | 9 | 2016 | 2990 | 0.430 |
Why?
| | Tobacco Use Disorder | 6 | 2020 | 244 | 0.420 |
Why?
| | Impulsive Behavior | 1 | 2015 | 151 | 0.410 |
Why?
| | Gene-Environment Interaction | 2 | 2014 | 189 | 0.400 |
Why?
| | Blood Pressure | 8 | 2018 | 1730 | 0.400 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 2037 | 0.400 |
Why?
| | Public Health | 1 | 2018 | 582 | 0.400 |
Why?
| | Aging | 6 | 2020 | 1852 | 0.390 |
Why?
| | Male | 74 | 2024 | 68035 | 0.390 |
Why?
| | Conduct Disorder | 5 | 2015 | 187 | 0.370 |
Why?
| | Female | 71 | 2024 | 73713 | 0.370 |
Why?
| | Breast Feeding | 1 | 2015 | 434 | 0.370 |
Why?
| | Natriuretic Peptide, Brain | 4 | 2024 | 97 | 0.360 |
Why?
| | Phenotype | 17 | 2020 | 3153 | 0.350 |
Why?
| | Sodium, Dietary | 4 | 2018 | 39 | 0.340 |
Why?
| | Genetic Loci | 4 | 2022 | 283 | 0.340 |
Why?
| | Carrier State | 2 | 2021 | 70 | 0.340 |
Why?
| | Sodium | 3 | 2018 | 197 | 0.330 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2010 | 50 | 0.310 |
Why?
| | Myocardium | 3 | 2020 | 907 | 0.310 |
Why?
| | Clinical Laboratory Techniques | 3 | 2020 | 94 | 0.300 |
Why?
| | Pedigree | 3 | 2013 | 511 | 0.300 |
Why?
| | Adult | 36 | 2020 | 38190 | 0.290 |
Why?
| | Apolipoprotein E4 | 2 | 2007 | 37 | 0.290 |
Why?
| | Risk Factors | 26 | 2022 | 10366 | 0.290 |
Why?
| | Apolipoprotein E2 | 1 | 2007 | 3 | 0.280 |
Why?
| | alpha-Macroglobulins | 1 | 2007 | 24 | 0.280 |
Why?
| | Biometry | 2 | 2007 | 68 | 0.270 |
Why?
| | Adolescent | 25 | 2021 | 21503 | 0.270 |
Why?
| | Young Adult | 17 | 2021 | 13298 | 0.270 |
Why?
| | Body Weight | 5 | 2015 | 985 | 0.260 |
Why?
| | Emergency Service, Hospital | 8 | 2020 | 2102 | 0.260 |
Why?
| | Multifactorial Inheritance | 2 | 2022 | 170 | 0.260 |
Why?
| | Middle Aged | 35 | 2024 | 33711 | 0.260 |
Why?
| | Blood Glucose | 9 | 2018 | 2190 | 0.250 |
Why?
| | Family | 7 | 2011 | 676 | 0.250 |
Why?
| | Memory | 1 | 2007 | 255 | 0.240 |
Why?
| | Aged | 32 | 2024 | 24134 | 0.240 |
Why?
| | Linkage Disequilibrium | 7 | 2020 | 260 | 0.240 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2005 | 34 | 0.240 |
Why?
| | Sodium Nitrite | 2 | 2015 | 39 | 0.240 |
Why?
| | Models, Genetic | 8 | 2016 | 590 | 0.230 |
Why?
| | Biomarkers | 11 | 2024 | 4101 | 0.230 |
Why?
| | Asymptomatic Infections | 2 | 2021 | 33 | 0.220 |
Why?
| | Filgrastim | 1 | 2024 | 12 | 0.220 |
Why?
| | Diet, Sodium-Restricted | 2 | 2016 | 38 | 0.220 |
Why?
| | Endothelium, Vascular | 3 | 2016 | 926 | 0.220 |
Why?
| | Heart Diseases | 2 | 2017 | 330 | 0.210 |
Why?
| | Internationality | 2 | 2022 | 158 | 0.210 |
Why?
| | HIV Infections | 3 | 2013 | 2943 | 0.210 |
Why?
| | Feeding and Eating Disorders | 2 | 2020 | 168 | 0.210 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2024 | 26 | 0.210 |
Why?
| | Population Health | 1 | 2024 | 48 | 0.200 |
Why?
| | Health Status | 2 | 2018 | 820 | 0.200 |
Why?
| | ROC Curve | 4 | 2017 | 565 | 0.200 |
Why?
| | Cooperative Behavior | 1 | 2005 | 457 | 0.190 |
Why?
| | Cholesterol, HDL | 3 | 2016 | 196 | 0.190 |
Why?
| | Prospective Studies | 10 | 2021 | 7611 | 0.190 |
Why?
| | Saliva | 2 | 2021 | 239 | 0.190 |
Why?
| | Viral Load | 2 | 2021 | 499 | 0.190 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3300 | 0.190 |
Why?
| | Nerve Tissue Proteins | 4 | 2011 | 597 | 0.190 |
Why?
| | Tobacco Use | 1 | 2022 | 63 | 0.190 |
Why?
| | Case-Control Studies | 15 | 2019 | 3574 | 0.190 |
Why?
| | Lipids | 3 | 2018 | 673 | 0.180 |
Why?
| | Peptide Fragments | 4 | 2024 | 691 | 0.180 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 1050 | 0.180 |
Why?
| | Hypertension | 4 | 2016 | 1252 | 0.170 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2012 | 68 | 0.170 |
Why?
| | Prediabetic State | 1 | 2024 | 247 | 0.170 |
Why?
| | Gastrointestinal Microbiome | 2 | 2020 | 699 | 0.170 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 746 | 0.170 |
Why?
| | Mental Disorders | 3 | 2019 | 1091 | 0.170 |
Why?
| | Receptors, GABA-A | 2 | 2014 | 139 | 0.170 |
Why?
| | Alleles | 5 | 2018 | 887 | 0.170 |
Why?
| | Diseases in Twins | 2 | 2012 | 159 | 0.170 |
Why?
| | Smoking | 5 | 2019 | 1601 | 0.160 |
Why?
| | Gene Frequency | 10 | 2011 | 504 | 0.160 |
Why?
| | Brachial Artery | 3 | 2016 | 202 | 0.160 |
Why?
| | Risk | 4 | 2020 | 908 | 0.160 |
Why?
| | Immunoassay | 1 | 2020 | 113 | 0.160 |
Why?
| | Multigene Family | 2 | 2011 | 200 | 0.150 |
Why?
| | Risk Assessment | 8 | 2020 | 3452 | 0.150 |
Why?
| | Reference Values | 4 | 2016 | 801 | 0.150 |
Why?
| | Genetic Markers | 4 | 2014 | 345 | 0.150 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 634 | 0.150 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 260 | 0.150 |
Why?
| | Data Interpretation, Statistical | 3 | 2011 | 362 | 0.150 |
Why?
| | Minisatellite Repeats | 1 | 2019 | 41 | 0.150 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 111 | 0.150 |
Why?
| | Global Health | 4 | 2016 | 382 | 0.150 |
Why?
| | Vascular Stiffness | 3 | 2018 | 443 | 0.150 |
Why?
| | Behavior | 1 | 2019 | 91 | 0.140 |
Why?
| | Schizophrenia | 3 | 2020 | 450 | 0.140 |
Why?
| | Healthy Aging | 1 | 2018 | 35 | 0.140 |
Why?
| | Biological Specimen Banks | 1 | 2019 | 100 | 0.140 |
Why?
| | Feces | 2 | 2020 | 480 | 0.140 |
Why?
| | Adolescent Behavior | 2 | 2013 | 530 | 0.140 |
Why?
| | Pandemics | 2 | 2024 | 1629 | 0.140 |
Why?
| | Genetic Association Studies | 4 | 2014 | 373 | 0.140 |
Why?
| | Sodium Pertechnetate Tc 99m | 2 | 1997 | 4 | 0.140 |
Why?
| | Students | 2 | 2021 | 625 | 0.140 |
Why?
| | Body Height | 2 | 2015 | 195 | 0.140 |
Why?
| | Marijuana Abuse | 1 | 2020 | 226 | 0.140 |
Why?
| | NAD | 1 | 2018 | 77 | 0.140 |
Why?
| | Likelihood Functions | 2 | 2015 | 143 | 0.140 |
Why?
| | Niacinamide | 1 | 2018 | 82 | 0.140 |
Why?
| | Exercise | 3 | 2018 | 2074 | 0.130 |
Why?
| | Caloric Restriction | 2 | 2018 | 124 | 0.130 |
Why?
| | Athletes | 1 | 2021 | 424 | 0.130 |
Why?
| | Mouth | 1 | 2017 | 87 | 0.130 |
Why?
| | Burns | 1 | 2021 | 335 | 0.130 |
Why?
| | Apolipoprotein B-100 | 1 | 2016 | 10 | 0.130 |
Why?
| | Cholesterol, LDL | 2 | 2016 | 359 | 0.130 |
Why?
| | Hair | 2 | 2015 | 88 | 0.130 |
Why?
| | Psychological Trauma | 1 | 2017 | 54 | 0.130 |
Why?
| | Apolipoprotein A-I | 1 | 2016 | 31 | 0.130 |
Why?
| | Regional Blood Flow | 2 | 2016 | 496 | 0.130 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2016 | 40 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 388 | 0.130 |
Why?
| | Chromosome Mapping | 5 | 2015 | 515 | 0.120 |
Why?
| | Trehalose | 1 | 2016 | 32 | 0.120 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2016 | 39 | 0.120 |
Why?
| | Europe | 5 | 2022 | 406 | 0.120 |
Why?
| | Gene Regulatory Networks | 2 | 2018 | 310 | 0.120 |
Why?
| | Cross-Sectional Studies | 6 | 2013 | 5518 | 0.120 |
Why?
| | Algorithms | 3 | 2020 | 1709 | 0.120 |
Why?
| | Aged, 80 and over | 7 | 2020 | 7683 | 0.120 |
Why?
| | Cohort Studies | 9 | 2020 | 5717 | 0.110 |
Why?
| | Sexual Partners | 2 | 2013 | 188 | 0.110 |
Why?
| | Educational Status | 2 | 2014 | 474 | 0.110 |
Why?
| | United States | 5 | 2016 | 14983 | 0.110 |
Why?
| | Amino Acids | 1 | 2018 | 499 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 30 | 0.110 |
Why?
| | Carotid Arteries | 1 | 2015 | 195 | 0.110 |
Why?
| | Quality Control | 1 | 2014 | 169 | 0.110 |
Why?
| | Health Surveys | 1 | 2016 | 521 | 0.110 |
Why?
| | Proteome | 1 | 2018 | 471 | 0.110 |
Why?
| | Odds Ratio | 6 | 2016 | 1080 | 0.100 |
Why?
| | Malawi | 1 | 2013 | 53 | 0.100 |
Why?
| | Hindlimb | 1 | 2014 | 133 | 0.100 |
Why?
| | Albuminuria | 1 | 2014 | 185 | 0.100 |
Why?
| | Income | 1 | 2014 | 204 | 0.100 |
Why?
| | Locomotion | 1 | 2014 | 105 | 0.100 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 22 | 0.100 |
Why?
| | Polymorphism, Genetic | 3 | 2012 | 634 | 0.100 |
Why?
| | Colorado | 4 | 2021 | 4526 | 0.100 |
Why?
| | Telomere | 1 | 2016 | 276 | 0.100 |
Why?
| | Aorta | 1 | 2015 | 415 | 0.100 |
Why?
| | Metabolomics | 1 | 2018 | 686 | 0.100 |
Why?
| | Physical Exertion | 1 | 2014 | 209 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 130 | 0.100 |
Why?
| | Double-Blind Method | 5 | 2018 | 1936 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 35 | 0.100 |
Why?
| | Metformin | 1 | 2016 | 335 | 0.100 |
Why?
| | Metabolic Networks and Pathways | 1 | 2014 | 184 | 0.100 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2024 | 2513 | 0.100 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1302 | 0.100 |
Why?
| | Myocardial Ischemia | 1 | 2014 | 259 | 0.090 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 75 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 538 | 0.090 |
Why?
| | Substance Abuse, Intravenous | 1 | 2013 | 117 | 0.090 |
Why?
| | Receptors, Oxytocin | 1 | 2012 | 22 | 0.090 |
Why?
| | Pravastatin | 1 | 1992 | 41 | 0.090 |
Why?
| | Lovastatin | 1 | 1992 | 38 | 0.090 |
Why?
| | Canada | 5 | 2007 | 409 | 0.090 |
Why?
| | Genetic Heterogeneity | 3 | 2008 | 59 | 0.090 |
Why?
| | Hyperlipoproteinemia Type II | 1 | 1992 | 31 | 0.090 |
Why?
| | Prevalence | 6 | 2017 | 2744 | 0.090 |
Why?
| | Age Factors | 6 | 2020 | 3262 | 0.090 |
Why?
| | Haplotypes | 6 | 2010 | 494 | 0.090 |
Why?
| | Puberty | 1 | 2013 | 152 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2021 | 1951 | 0.090 |
Why?
| | Ramipril | 2 | 2008 | 6 | 0.090 |
Why?
| | Physical Fitness | 1 | 2013 | 206 | 0.090 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2011 | 8 | 0.090 |
Why?
| | Postural Balance | 1 | 2014 | 218 | 0.090 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2011 | 39 | 0.090 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2011 | 55 | 0.090 |
Why?
| | Potassium | 1 | 2011 | 145 | 0.090 |
Why?
| | Software | 2 | 2014 | 665 | 0.090 |
Why?
| | Interleukins | 1 | 2013 | 251 | 0.090 |
Why?
| | Receptors, Immunologic | 2 | 2013 | 215 | 0.090 |
Why?
| | Receptors, Dopamine D4 | 1 | 2011 | 25 | 0.090 |
Why?
| | Motor Activity | 1 | 2015 | 711 | 0.090 |
Why?
| | Glucose Metabolism Disorders | 1 | 2010 | 11 | 0.080 |
Why?
| | Behavior, Animal | 1 | 2014 | 509 | 0.080 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2011 | 59 | 0.080 |
Why?
| | Diabetes Mellitus | 3 | 2011 | 1054 | 0.080 |
Why?
| | Follow-Up Studies | 6 | 2024 | 5160 | 0.080 |
Why?
| | Child Behavior Disorders | 1 | 2011 | 142 | 0.080 |
Why?
| | Catechol O-Methyltransferase | 1 | 2010 | 19 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 196 | 0.080 |
Why?
| | Diet, Reducing | 1 | 2010 | 91 | 0.080 |
Why?
| | Hepatitis C | 1 | 2013 | 274 | 0.080 |
Why?
| | Life Expectancy | 1 | 2010 | 70 | 0.080 |
Why?
| | Quality of Life | 1 | 2021 | 2952 | 0.080 |
Why?
| | Tissue Donors | 1 | 2013 | 416 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 759 | 0.080 |
Why?
| | Environment | 2 | 2010 | 338 | 0.080 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2017 | 847 | 0.080 |
Why?
| | Psychology, Adolescent | 1 | 2009 | 68 | 0.080 |
Why?
| | Twins, Dizygotic | 1 | 2010 | 162 | 0.080 |
Why?
| | Isotretinoin | 1 | 2009 | 24 | 0.080 |
Why?
| | Hyperhomocysteinemia | 1 | 2009 | 27 | 0.080 |
Why?
| | Acne Vulgaris | 1 | 2009 | 25 | 0.080 |
Why?
| | Ontario | 2 | 2020 | 95 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 189 | 0.070 |
Why?
| | Insulin Glargine | 2 | 2022 | 84 | 0.070 |
Why?
| | Energy Metabolism | 1 | 2015 | 920 | 0.070 |
Why?
| | Hypertriglyceridemia | 1 | 2009 | 39 | 0.070 |
Why?
| | Genes, Neoplasm | 1 | 2008 | 22 | 0.070 |
Why?
| | Longevity | 1 | 2010 | 174 | 0.070 |
Why?
| | Benzoates | 1 | 2008 | 45 | 0.070 |
Why?
| | Dermatologic Agents | 1 | 2009 | 67 | 0.070 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 38 | 0.070 |
Why?
| | Homocysteine | 1 | 2009 | 159 | 0.070 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5860 | 0.070 |
Why?
| | Raphe Nuclei | 2 | 1999 | 109 | 0.070 |
Why?
| | Myosin Type V | 1 | 2008 | 9 | 0.070 |
Why?
| | Proteinuria | 1 | 2008 | 97 | 0.070 |
Why?
| | Universities | 2 | 2021 | 440 | 0.070 |
Why?
| | Cognition | 1 | 2015 | 1172 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 188 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2857 | 0.070 |
Why?
| | Benzimidazoles | 1 | 2008 | 174 | 0.070 |
Why?
| | Death | 2 | 2018 | 122 | 0.070 |
Why?
| | Prognosis | 4 | 2021 | 4017 | 0.060 |
Why?
| | Myosin Heavy Chains | 1 | 2008 | 177 | 0.060 |
Why?
| | Triglycerides | 2 | 2003 | 515 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 1 | 2006 | 54 | 0.060 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 188 | 0.060 |
Why?
| | China | 3 | 2007 | 213 | 0.060 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 426 | 0.060 |
Why?
| | Pharmacogenetics | 1 | 2007 | 165 | 0.060 |
Why?
| | Sex Factors | 4 | 2017 | 2055 | 0.060 |
Why?
| | Heart Failure | 2 | 2011 | 2053 | 0.060 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2005 | 31 | 0.060 |
Why?
| | Parkinson Disease | 1 | 2012 | 546 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2005 | 115 | 0.060 |
Why?
| | Antigens, Neoplasm | 1 | 2008 | 317 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2008 | 500 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2013 | 843 | 0.060 |
Why?
| | Biological Availability | 2 | 2012 | 134 | 0.060 |
Why?
| | Hematologic Agents | 1 | 2024 | 2 | 0.060 |
Why?
| | Febrile Neutropenia | 1 | 2024 | 6 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2008 | 611 | 0.060 |
Why?
| | Chemical Phenomena | 1 | 2024 | 82 | 0.060 |
Why?
| | Ankle Brachial Index | 1 | 2024 | 37 | 0.050 |
Why?
| | Comorbidity | 4 | 2013 | 1645 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1136 | 0.050 |
Why?
| | Anxiety Disorders | 2 | 2021 | 375 | 0.050 |
Why?
| | Metabolome | 2 | 2018 | 351 | 0.050 |
Why?
| | Tobacco Products | 2 | 2019 | 132 | 0.050 |
Why?
| | Cognition Disorders | 1 | 2007 | 504 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 201 | 0.050 |
Why?
| | Chlamydophila Infections | 1 | 2003 | 5 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2006 | 1314 | 0.050 |
Why?
| | Hepatitis A | 1 | 2003 | 26 | 0.050 |
Why?
| | Telephone | 1 | 2024 | 181 | 0.050 |
Why?
| | Helicobacter Infections | 1 | 2003 | 30 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2003 | 83 | 0.050 |
Why?
| | Muscle, Skeletal | 1 | 2013 | 1739 | 0.050 |
Why?
| | Sample Size | 1 | 2022 | 124 | 0.050 |
Why?
| | Time Factors | 3 | 2020 | 6848 | 0.050 |
Why?
| | Child | 8 | 2021 | 21862 | 0.050 |
Why?
| | Depressive Disorder, Major | 2 | 2020 | 374 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2014 | 2678 | 0.050 |
Why?
| | Mental Status and Dementia Tests | 1 | 2022 | 25 | 0.050 |
Why?
| | Evaluation Studies as Topic | 2 | 2020 | 174 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2024 | 411 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 610 | 0.040 |
Why?
| | Incidence | 2 | 2019 | 2820 | 0.040 |
Why?
| | Logistic Models | 2 | 2016 | 2083 | 0.040 |
Why?
| | Dietary Supplements | 2 | 2015 | 562 | 0.040 |
Why?
| | Kidney Diseases | 1 | 2005 | 407 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2021 | 38 | 0.040 |
Why?
| | Pilot Projects | 2 | 2017 | 1743 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2003 | 192 | 0.040 |
Why?
| | Virion | 1 | 2021 | 113 | 0.040 |
Why?
| | Kidney | 1 | 2008 | 1471 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2027 | 0.040 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 237 | 0.040 |
Why?
| | Patient Selection | 2 | 2008 | 692 | 0.040 |
Why?
| | Luminescence | 1 | 2020 | 37 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 102 | 0.040 |
Why?
| | Serotonin | 2 | 1999 | 322 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2020 | 52 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1049 | 0.040 |
Why?
| | Specimen Handling | 1 | 2021 | 182 | 0.040 |
Why?
| | Opioid Peptides | 1 | 1999 | 9 | 0.040 |
Why?
| | Hyperglycemia | 1 | 2003 | 347 | 0.040 |
Why?
| | Escape Reaction | 1 | 1999 | 58 | 0.040 |
Why?
| | Asia, Southeastern | 1 | 1998 | 12 | 0.040 |
Why?
| | Computer Simulation | 3 | 2010 | 989 | 0.040 |
Why?
| | Genetics, Behavioral | 1 | 2019 | 34 | 0.040 |
Why?
| | Apolipoproteins | 2 | 2004 | 34 | 0.040 |
Why?
| | Helplessness, Learned | 1 | 1999 | 68 | 0.040 |
Why?
| | Potassium, Dietary | 1 | 2018 | 12 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 411 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1476 | 0.040 |
Why?
| | Infusions, Intravenous | 2 | 1997 | 400 | 0.040 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 28 | 0.040 |
Why?
| | United Kingdom | 1 | 2019 | 319 | 0.030 |
Why?
| | Oxidative Stress | 2 | 2016 | 1319 | 0.030 |
Why?
| | Methionine | 1 | 2018 | 162 | 0.030 |
Why?
| | Limit of Detection | 1 | 2017 | 87 | 0.030 |
Why?
| | Chromosomes, Human | 1 | 2017 | 45 | 0.030 |
Why?
| | Transcription Factors | 1 | 2005 | 1707 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2017 | 21 | 0.030 |
Why?
| | Hospitalization | 2 | 2021 | 2203 | 0.030 |
Why?
| | Absorption | 1 | 1997 | 60 | 0.030 |
Why?
| | Troponin | 1 | 2017 | 50 | 0.030 |
Why?
| | RNA, Viral | 1 | 2021 | 688 | 0.030 |
Why?
| | Anxiety | 2 | 2021 | 1063 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 1997 | 162 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2017 | 188 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 969 | 0.030 |
Why?
| | Models, Biological | 2 | 2010 | 1785 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2017 | 336 | 0.030 |
Why?
| | Methemoglobin | 1 | 2015 | 21 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 355 | 0.030 |
Why?
| | Forearm | 1 | 2016 | 138 | 0.030 |
Why?
| | Fear | 1 | 1999 | 343 | 0.030 |
Why?
| | Stress, Physiological | 1 | 1999 | 454 | 0.030 |
Why?
| | Acetylcholine | 1 | 2016 | 205 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2016 | 123 | 0.030 |
Why?
| | Fatty Acids | 1 | 2018 | 445 | 0.030 |
Why?
| | Mice, Congenic | 1 | 2015 | 23 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 735 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2008 | 2530 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 553 | 0.030 |
Why?
| | Elasticity | 1 | 2015 | 194 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2008 | 759 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 425 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 523 | 0.030 |
Why?
| | Pulse Wave Analysis | 1 | 2015 | 233 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1479 | 0.030 |
Why?
| | Brain Chemistry | 2 | 2009 | 115 | 0.030 |
Why?
| | Sibling Relations | 1 | 2014 | 11 | 0.030 |
Why?
| | Urban Health | 1 | 2014 | 96 | 0.030 |
Why?
| | Regression Analysis | 1 | 1997 | 1014 | 0.030 |
Why?
| | Rural Health | 1 | 2014 | 83 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1006 | 0.030 |
Why?
| | Inheritance Patterns | 1 | 2014 | 44 | 0.030 |
Why?
| | Mobility Limitation | 1 | 2014 | 60 | 0.030 |
Why?
| | Unsafe Sex | 1 | 2013 | 63 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 9 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 397 | 0.020 |
Why?
| | Condoms | 1 | 2013 | 102 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2158 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1287 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 1934 | 0.020 |
Why?
| | Vasodilation | 1 | 2015 | 510 | 0.020 |
Why?
| | Microcirculation | 1 | 2012 | 148 | 0.020 |
Why?
| | Research Design | 1 | 1998 | 1117 | 0.020 |
Why?
| | Genomics | 1 | 2017 | 804 | 0.020 |
Why?
| | Mice | 3 | 2015 | 17761 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1992 | 104 | 0.020 |
Why?
| | Urinalysis | 1 | 2011 | 77 | 0.020 |
Why?
| | Interferons | 1 | 2013 | 202 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2012 | 367 | 0.020 |
Why?
| | Muscle Strength | 1 | 2014 | 317 | 0.020 |
Why?
| | Infusions, Parenteral | 1 | 1991 | 41 | 0.020 |
Why?
| | Urban Population | 1 | 2014 | 481 | 0.020 |
Why?
| | Phobic Disorders | 1 | 2011 | 33 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2015 | 890 | 0.020 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2011 | 61 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2012 | 550 | 0.020 |
Why?
| | Sodium Chloride | 1 | 1991 | 138 | 0.020 |
Why?
| | Neurons | 1 | 1999 | 1594 | 0.020 |
Why?
| | Rodentia | 1 | 2010 | 59 | 0.020 |
Why?
| | Recovery of Function | 1 | 2014 | 666 | 0.020 |
Why?
| | Animals | 5 | 2015 | 37129 | 0.020 |
Why?
| | Fluid Therapy | 1 | 1991 | 134 | 0.020 |
Why?
| | Nuclear Family | 1 | 2009 | 57 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 409 | 0.020 |
Why?
| | Dizziness | 1 | 2010 | 82 | 0.020 |
Why?
| | Coronary Disease | 1 | 1992 | 374 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1102 | 0.020 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2009 | 6 | 0.020 |
Why?
| | Vitamin B 6 | 1 | 2009 | 10 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2010 | 191 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1093 | 0.020 |
Why?
| | Inflammation | 1 | 2020 | 2843 | 0.020 |
Why?
| | Fertility | 1 | 2010 | 164 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2009 | 66 | 0.020 |
Why?
| | Vitamin B Complex | 1 | 2009 | 42 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 524 | 0.020 |
Why?
| | Tetraspanins | 1 | 2008 | 19 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2009 | 126 | 0.020 |
Why?
| | Pyrroles | 1 | 2009 | 211 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2008 | 70 | 0.020 |
Why?
| | Medical History Taking | 1 | 2008 | 117 | 0.020 |
Why?
| | Folic Acid | 1 | 2009 | 188 | 0.020 |
Why?
| | Sri Lanka | 1 | 2007 | 7 | 0.020 |
Why?
| | Internet | 1 | 2012 | 674 | 0.020 |
Why?
| | Pakistan | 1 | 2007 | 76 | 0.020 |
Why?
| | Bangladesh | 1 | 2007 | 56 | 0.020 |
Why?
| | Bias | 1 | 2008 | 224 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2009 | 298 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 356 | 0.020 |
Why?
| | Anticholesteremic Agents | 1 | 2009 | 151 | 0.020 |
Why?
| | Energy Intake | 1 | 2010 | 506 | 0.020 |
Why?
| | India | 1 | 2007 | 197 | 0.020 |
Why?
| | Creatinine | 1 | 2008 | 487 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 902 | 0.020 |
Why?
| | Age of Onset | 1 | 2007 | 519 | 0.020 |
Why?
| | Genes, Recessive | 1 | 2006 | 78 | 0.020 |
Why?
| | Glucose Tolerance Test | 1 | 2007 | 366 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1043 | 0.010 |
Why?
| | Data Collection | 1 | 2008 | 661 | 0.010 |
Why?
| | Dyslipidemias | 1 | 2007 | 169 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 1237 | 0.010 |
Why?
| | Asthma | 2 | 2010 | 1888 | 0.010 |
Why?
| | Linear Models | 1 | 2007 | 851 | 0.010 |
Why?
| | Placebos | 1 | 2005 | 197 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2005 | 145 | 0.010 |
Why?
| | Vitamin E | 1 | 2005 | 123 | 0.010 |
Why?
| | Heterozygote | 1 | 2005 | 305 | 0.010 |
Why?
| | Body Constitution | 1 | 2004 | 54 | 0.010 |
Why?
| | Smoking Cessation | 1 | 2008 | 431 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1284 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1872 | 0.010 |
Why?
| | Cross-Cultural Comparison | 1 | 2004 | 85 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4308 | 0.010 |
Why?
| | Fasting | 1 | 2005 | 282 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 2005 | 250 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 2 | 1999 | 2472 | 0.010 |
Why?
| | RNA | 1 | 2010 | 927 | 0.010 |
Why?
| | Hepatitis A virus | 1 | 2003 | 2 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2005 | 304 | 0.010 |
Why?
| | Chlamydophila pneumoniae | 1 | 2003 | 12 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5770 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 462 | 0.010 |
Why?
| | Asia | 1 | 2003 | 71 | 0.010 |
Why?
| | Helicobacter pylori | 1 | 2003 | 42 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2004 | 226 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 15842 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 2003 | 164 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 571 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 2003 | 146 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2003 | 159 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 361 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1032 | 0.010 |
Why?
| | Glucose Intolerance | 1 | 2003 | 146 | 0.010 |
Why?
| | DNA | 1 | 2008 | 1448 | 0.010 |
Why?
| | Parents | 1 | 2010 | 1419 | 0.010 |
Why?
| | Rats | 2 | 1999 | 5565 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2004 | 1308 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2006 | 1152 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1313 | 0.010 |
Why?
| | Reinforcement Schedule | 1 | 1999 | 31 | 0.010 |
Why?
| | Microinjections | 1 | 1999 | 86 | 0.010 |
Why?
| | Electroshock | 1 | 1999 | 143 | 0.010 |
Why?
| | Periaqueductal Gray | 1 | 1999 | 38 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2003 | 649 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2007 | 1225 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1999 | 188 | 0.010 |
Why?
| | Catheterization | 1 | 1999 | 180 | 0.010 |
Why?
| | Naltrexone | 1 | 1999 | 99 | 0.010 |
Why?
| | Morphine | 1 | 1999 | 161 | 0.010 |
Why?
| | Narcotic Antagonists | 1 | 1999 | 184 | 0.010 |
Why?
| | Diet | 1 | 2004 | 1287 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2405 | 0.010 |
Why?
| | Infant | 1 | 2008 | 9553 | 0.010 |
Why?
| | Child, Preschool | 1 | 2008 | 11115 | 0.010 |
Why?
| | Hyaluronoglucosaminidase | 1 | 1991 | 8 | 0.010 |
Why?
| | Tritium | 1 | 1991 | 72 | 0.010 |
Why?
| | Analgesics, Opioid | 1 | 1999 | 1049 | 0.010 |
Why?
| | Depression | 1 | 1999 | 1464 | 0.000 |
Why?
|
|
McQueen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|